CariprazineD2/D3 partial agonist,antipsychotic drug CAS# 839712-12-8 |
- Dexpramipexole dihydrochloride
Catalog No.:BCC1528
CAS No.:104632-27-1
- Dexpramipexole
Catalog No.:BCC1527
CAS No.:104632-28-2
- Cariprazine hydrochloride
Catalog No.:BCC1454
CAS No.:1083076-69-0
- L-Stepholidine
Catalog No.:BCN2599
CAS No.:16562-13-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 839712-12-8 | SDF | Download SDF |
| PubChem ID | 11154555 | Appearance | Powder |
| Formula | C21H32Cl2N4O | M.Wt | 427.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | RGH-188 | ||
| Solubility | Soluble in DMSO | ||
| Chemical Name | 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea | ||
| SMILES | CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl | ||
| Standard InChIKey | KPWSJANDNDDRMB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Cariprazine is a novel antipsychotic drug candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM).In Vitro:Cariprazine stimulates inositol phosphate (IP) formation with a high potency (pEC50 8.5) with relatively low efficacy (Emax 30%)[2]. Cariprazine, a novel candidate antipsychotic, demonstrated approximately 10-fold higher affinity for human D3 versus human D2L and human D2S receptors (pKi 10.07, 9.16, and 9.31, respectively). Cariprazine displays high affinity at human serotonin (5-HT) type 2B receptors (pKi 9.24) with pure antagonism. Cariprazine has lower affinity at human and rat hippocampal 5-HT1A receptors (pKi 8.59 and 8.34, respectively) and demonstrates low intrinsic efficacy. Cariprazine displays low affinity at human 5-HT2A receptors (pKi 7.73). Moderate or low affinity for histamine H1 and 5-HT2C receptors (pKi 7.63 and 6.87, respectively) suggest Cariprazine's reduced propensity for adverse events related to these receptors[2]. Cariprazine is over sixfold more potent (EC50=1.4 nM) than Aripiprazole (EC50=9.2 nM) in inhibiting isoproterenol-induced cAMP production in HEK-293 cells[4].In Vivo:Administration of Cariprazine (30 µg/kg) reduces the striatal uptake of both radioligands to the level of nonspecific binding compared with baseline PET measurements. Cariprazine has negligible effect on the time-activity curves in the cerebellum. At doses of 5.0 and 30 µg/kg, Cariprazine causes a dose-dependent dopamine D2/D3 receptor occupancy of ~45% and ~80% for both antagonist [11C] raclopride and agonist radioligand [11C]MNPA. Receptor occupancy of dopamine D2/D3 receptors calculated using the transient equilibrium and the MRTM2 methods ranged from 5% at the lowest dose (1.0 µg/kg) to 94% at the highest dose (300 µg/kg)[1]. The effects of 5 doses of Cariprazine (ranging from 0.005 to 0.15 mg/kg) are examined on EPM behavior of wild-type mice. Whereas lower doses of Cariprazine (0.005 to 0.02 mg/kg) do not alter the time spent in open arms, the two higher doses (0.08 and 0.15 mg/kg) lead to a significant decline of this measure (ANOVA, (F(5,52)=4.20; p=0.0032)). Moreover, the two higher doses of Cariprazine also lead to a significant decrease in the total number of arm entries (F(5,52)=7.21; p=0.0001)) but this decrease in the total number of arm entries is largely accounted for by a significant decrease in the number of closed arm entries (F(5,52)=11.75; p=0.0001)). The two highest doses of Cariprazine (0.08 and 0.15 mg/kg) have significant effects on locomotor activity, but doses ranging from 0.005 to 0.02 mg/kg do not affect anxiety-like behavior or locomotor activity in the EPM test[3]. A significant (P<0.01) reduction in ouabain-induced hyperactivity is observed after acute i.p. administration of all doses of Cariprazine (mean±SEM: 0.06 mg/kg, 64.2±3.88; 0.25 mg/kg, 72.7±11.67; 0.5 mg/kg, 40.6±5.32; 1 mg/kg, 19.5±8.78) and lithium (40.4±12.78), compared with ouabain injection alone (114.6±14.33). The highest Cariprazine dose produced significant sedation (72% inhibition for Cariprazine 1.0 mg/kg aCSF vs. saline aCSF; P<0.05)[4]. References: | |||||
Cariprazine Dilution Calculator
Cariprazine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3397 mL | 11.6984 mL | 23.3967 mL | 46.7935 mL | 58.4918 mL |
| 5 mM | 0.4679 mL | 2.3397 mL | 4.6793 mL | 9.3587 mL | 11.6984 mL |
| 10 mM | 0.234 mL | 1.1698 mL | 2.3397 mL | 4.6793 mL | 5.8492 mL |
| 50 mM | 0.0468 mL | 0.234 mL | 0.4679 mL | 0.9359 mL | 1.1698 mL |
| 100 mM | 0.0234 mL | 0.117 mL | 0.234 mL | 0.4679 mL | 0.5849 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description: IC50 Value: 0.5 and 0.09 nM (Ki for D2 and D3 receptor respectively); 2.6 and 180 nM(Ki for 5-HT1A and 5-HT2A receptor respectively) [1] Cariprazine is a novel antipsychotic drug candidate that exhibits high selectivity and affinity to dopamine D(3) and D(2) receptors and moderate affinity to serotonin 5-HT(1A) receptors. in vitro: Cariprazine had lower affinity at human and rat hippocampal 5-HT(1A) receptors (pK(i) 8.59 and 8.34, respectively) and demonstrated low intrinsic efficacy.Cariprazine displayed low affinity at human 5-HT(2A) receptors (pK(i) 7.73). Moderate or low affinity for histamine H(1) and 5-HT(2C) receptors (pK(i) 7.63 and 6.87, respectively) suggest cariprazine's reduced propensity for adverse events related to these receptors [2]. in vivo: Doses ≥ 1.5 mg/d yielded 69 - 75% D2/D3 receptor occupancy as measured in positron emission tomography scans. Mean half-life for cariprazine was 2 - 5 d over a dose range of 1.5 - 12.5 mg [3]. Cariprazine, as well as aripiprazole and bifeprunox, were able to reduce the rewarding effect of cocaine (minimum effective doses were 0.17, 1, and 0.1 mg/kg, respectively) and attenuated relapse to cocaine seeking with half maximal effective dose [ED??] values of 0.2, 4.2, and 0.17 mg/kg, respectively [4]. Toxicity: In the fixed-dose study of cariprazine that tested 1.5, 3.0, and 4.5 mg/day, the most commonly encountered adverse events were insomnia, extrapyramidal disorder, sedation, akathisia, nausea, dizziness, vomiting, anxiety, and constipation [5]. Clinical trial: Cariprazine is in phase III clinical trials in patients with schizophrenia and in patients with bipolar disorder.
- 2,7-Dimethyl-1,4-dihydroxynaphthalene 1-O-glucoside
Catalog No.:BCN7611
CAS No.:839711-70-5
- Pluripotin
Catalog No.:BCC6178
CAS No.:839707-37-8
- GNF-7
Catalog No.:BCC6529
CAS No.:839706-07-9
- 4-Epicommunic acid
Catalog No.:BCN4382
CAS No.:83945-57-7
- Flavidinin
Catalog No.:BCN3599
CAS No.:83925-00-2
- Flavidin
Catalog No.:BCN6438
CAS No.:83924-98-5
- Mometasone furoate
Catalog No.:BCC4801
CAS No.:83919-23-7
- Isogomisin O
Catalog No.:BCN4381
CAS No.:83916-76-1
- 13-Hydroxylabda-8(17),14-dien-18-oic acid
Catalog No.:BCN1332
CAS No.:83915-59-7
- 12-Acetoxyabietic acid
Catalog No.:BCN4380
CAS No.:83905-81-1
- Gramodendrine
Catalog No.:BCN2155
CAS No.:83905-67-3
- Azithromycin
Catalog No.:BCC4385
CAS No.:83905-01-5
- Hexestrol
Catalog No.:BCC4484
CAS No.:84-16-2
- Rutaecarpine
Catalog No.:BCN4385
CAS No.:84-26-4
- Ophiohayatone C
Catalog No.:BCN3608
CAS No.:84-33-3
- Syrosingopine
Catalog No.:BCN5365
CAS No.:84-36-6
- Stylopine
Catalog No.:BCN3715
CAS No.:84-39-9
- Tectoquinone
Catalog No.:BCN3481
CAS No.:84-54-8
- Anthraflavic acid
Catalog No.:BCC8831
CAS No.:84-60-6
- Anthraquinone
Catalog No.:BCC8832
CAS No.:84-65-1
- Diisobutyl phthalate
Catalog No.:BCN7148
CAS No.:84-69-5
- Dibutyl Phthalate
Catalog No.:BCC8411
CAS No.:84-74-2
- Lapachol
Catalog No.:BCN4391
CAS No.:84-79-7
- Vitamin K1
Catalog No.:BCN2209
CAS No.:84-80-0
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.[Pubmed:28185672]
Lancet. 2017 Mar 18;389(10074):1103-1113.
BACKGROUND: Although predominant negative symptoms of schizophrenia can be severe enough to cause persistent impairment, effective treatment options are lacking. We aimed to assess the new generation antipsychotic Cariprazine in adult patients with predominant negative symptoms. METHODS: In this randomised, double-blind, phase 3b trial, we enrolled adults aged 18-65 years with long-term (>2 year), stable schizophrenia and predominant negative symptoms (>6 months) at 66 study centres (mainly hospitals and university clinics, with a small number of private practices) in 11 European countries. Patients were randomly assigned (1:1) by an interactive web response system to 26 weeks of monotherapy with fixed-dose oral Cariprazine (3 mg, 4.5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6 mg per day); previous medication was discontinued over 2 weeks. The primary outcome was change from baseline to week 26 or end of treatment on the Positive and Negative Syndrome Scale factor score for negative symptoms (PANSS-FSNS) analysed in a modified intention-to-treat population of patients who had follow-up assessments within 5 days after last receipt of study drugs with a mixed-effects model for repeated measures. Safety was assessed in all patients who received at least one dose of study drug. This study is registered with EudraCT, number 2012-005485-36. FINDINGS: Between May 27, 2013, and Nov 17, 2014, 533 patients were screened and 461 (86%) patients were randomised to treatment (230 for Cariprazine and 231 for risperidone); 460 were included in the safety population (one patient discontinued before study drug intake). 227 (99%) of 230 patients in the Cariprazine group and 229 (99%) of 230 patients in the risperidone group were included in the modified intention-to-treat population (178 [77%] in each group completed 26 weeks of treatment). Mean daily doses were 4.2 mg (SD 0.6) for Cariprazine and 3.8 mg (0.4) for risperidone. Treatment-emergent adverse events (eg, insomnia, akathisia, worsening of schizophrenia, headache, anxiety) were reported in 123 (54%) patients treated with Cariprazine and 131 (57%) patients treated with risperidone. Use of Cariprazine led to a greater least squares mean change in PANSS-FSNS from baseline to week 26 than did risperidone (-8.90 points for Cariprazine vs -7.44 points for risperidone; least squares mean difference -1.46, 95% CI -2.39 to -0.53; p=0.0022; effect size 0.31). One patient in the risperidone group died of a cause regarded as unrelated to treatment. INTERPRETATION: Our results support the efficacy of Cariprazine in the treatment of predominant negative symptoms of schizophrenia. FUNDING: Gedeon Richter Plc.
Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.[Pubmed:28059046]
CNS Spectr. 2017 Dec;22(6):484-494.
OBJECTIVE: This study examined the chronic effects of aripiprazole and Cariprazine on serotonin (5-HT1A and 5-HT2A) and glutamate (NMDA and AMPA) receptor subtypes. In addition, the effects of aripiprazole on D2 and D3 receptors were tested and compared with previously reported Cariprazine data. METHODS: Rats received vehicle, aripiprazole (2, 5, or 15 mg/kg), or Cariprazine (0.06, 0.2, or 0.6 mg/kg) for 28 days. Receptor levels were quantified using autoradiographic assays on brain sections from the medial prefrontal cortex (MPC), dorsolateral frontal cortex (DFC), nucleus accumbens (NAc), caudate-putamen medial (CPu-M), caudate-putamen lateral (CPu-L), hippocampal CA1 (HIPP-CA1) and CA3 (HIPP-CA3) regions, and the entorhinal cortex (EC). RESULTS: Similar to previous findings with Cariprazine, aripiprazole upregulated D2 receptor levels in various regions; D3 receptor changes were less than those reported with Cariprazine. All aripiprazole doses and higher Cariprazine doses increased 5-HT1A receptors in the MPC and DFC. Higher aripiprazole and all Cariprazine doses increased 5-HT1A receptors in HIPP-CA1 and HIPP-CA3. Aripiprazole decreased 5-HT2A receptors in the MPC, DFC, HIPP-CA1, and HIPP-CA3 regions. Both compounds decreased NMDA receptors and increased AMPA receptors in select brain regions. CONCLUSIONS: Long-term administration of aripiprazole and Cariprazine had similar effects on 5-HT1A, NMDA, and AMPA receptors. However, Cariprazine more profoundly increased D3 receptors while aripiprazole selectively reduced 5-HT2A receptors. These results suggest that the unique actions of Cariprazine on dopamine D3 receptors, combined with its effects on serotonin and glutamate receptor subtypes, may confer the clinical benefits, safety, and tolerability of this novel compound in schizophrenia and bipolar mania.
Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole.[Pubmed:28101322]
Ther Adv Psychopharmacol. 2017 Jan;7(1):29-41.
BACKGROUND: Brexpiprazole and Cariprazine are the latest US Food and Drug Administration approved atypical antipsychotics available in the United States. Both function as partial agonists of the dopamine-2 receptor (D2R), a mechanism of action shared with aripiprazole. However, all three differ in their affinities for the D2R as well as for serotonin receptors (5-HTRs). This paper seeks to delineate these pharmacodynamic and clinical differences amongst the three dopamine partial agonist atypical antipsychotic drugs. METHODS: PubMed and clinicaltrials.gov searches were used to generate preclinical and clinical evidence for review. Data derived from animal models and human subjects were used to provide insight on clinical mechanisms and adverse effect potentials. Clinical trial data were reviewed to compare clinical efficacy and adverse effects. RESULTS: Efficacies among the three drugs are comparable for their shared indications. Side-effect profile and underlying pharmacodynamic mechanism of action for each drug may differ. CONCLUSION: Partial agonism of the D2R is a similarity of the three drugs reviewed. Each drug varies in affinity for both the D2R and a diverse group of 5-HTRs, generating a distinct profile of clinical indications and adverse effects for each.
